BCL2L1 and ovarian cancer: Interestingly, compared with mammary glands of AL mice, those from DR mice displayed robust induction of the receptor tyrosine kinases, IGF1R and EGFR, as well as the anti-apoptotic protein Bcl-xL (Fig. 1a and Supplementary Fig. 1a), reminiscent of the adaptive response observed in breast and ovarian cancer cells treated with the PI3K/mTOR inhibitor BEZ235 (ref. 9).